Champignon Brands Appoints Dr Joseph Gabriele To Special Advisory Committee

Champignon Brands (CSE: SHRM) this morning announced that it is bolstering its special advisory committee through the appointment of Dr Joseph Gabriele, a molecular pharmacologist specializing in signal transduction within the central nervous system.

Gabriele is expected to be responsible for championing Champignon’s development and commercialization of rapid onset treatments which are capable of improving health outcomes. The special advisory committee as a whole is expected to evaluate potential positive effects that its medicinal mushroom formulations may have on individuals suffering from depression or post traumatic stress disorder, as well as substance and alcohol use disorders.

Gabriele himself is specialized in molecular pharmacology, transdermal delivery, and formulation chemistry with pharmaceutical, natural molecules. Most recently he lead Delivra, which was later acquired by Harvest One Cannabis (TSXV: HVT), where he developed a transdermal delivery platform that can be tailored to deliver drugs via the skin to the skin derma, circulatory system, or muscles.

Dr. Gabriele’s established research credentials, entrepreneurial nature and relentless pursuit of medical innovation represents the desired skill sets that Champignon needs as we accelerate our accession into the psychedelic medicine arena. The appointment of Dr. Gabriele equips us with both a celebrated medical researcher, as well as a seasoned CPG formulation specialist, which will allow for the continued development of our mushroom-infused health products, novel delivery systems and eventual drug discovery initiatives.

Gareth Birdsall, CEO of Champignon Brands

Champignon Brands last traded at $0.30 on the CSE.

Silver47 Exploration Inc. — sponsored Sponsored · Silver47 Exploration Inc.

FULL DISCLOSURE: Champignon Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Champignon Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Red Cloud Fall Mining Showcase 2026 | Day 2

More Gold Without a Bigger Upfront Bill? | Keith Boyle – New Found Gold

The Red Cloud Fall Mining Showcase 2026 | Day 1

Recommended

First Majestic Lifts Q3 Revenue 38% to US$394.1 Million on Higher Silver Prices

Meghan Markle’s Half-Brother Submitted Evidence Against Their Father, But Now Faces Philippine Police Scrutiny

Related News

Shroom Rush? Champignon Announces $10M Bought Deal

This afternoon Champignon Brands Inc. (CSE: SHRM) announced they entered into an agreement on a...

Monday, May 11, 2020, 05:03:14 PM

Harvest Moon: Reducing Suicidal Ideation With Ketamine Infusions

Suicidal ideation is an emergent condition that demands immediate attention. It has been shown that...

Tuesday, May 26, 2020, 03:00:00 PM

Champignon Brands Announces Contract Research Partner For Ketamine, Psilocybin IP Portfolio

Champignon Brands (CSE: SHRM) announced this morning that it is advancing its drug discovery program...

Monday, June 8, 2020, 10:03:37 AM

Champignon Brands Files Required Disclosures With Exchange, Resumption Of Trading In Hands Of BCSC

Champignon Brands (CSE: SHRM) has completed the regulatory filings required as per the review previously...

Friday, July 24, 2020, 05:33:15 PM

Market Movers: Champignon Brands Tags $2; Up Over 35%

This morning Champignon Brands (CSE: SHRM) continued to gain momentum as the stock increased to...

Friday, May 15, 2020, 11:39:20 AM